Literature DB >> 667526

A linear transform of the multi-target survival curve.

J V Watson.   

Abstract

A completely linear transform of the multi-target survival curve is presented. This enables all data, including those on the shoulder region of the curve, to be analysed. The necessity to make a subjective assessment about which data points to exclude for conventional methods of analysis is, therefore, removed. The analysis has also been adapted to include a "Pike-Alper" method of assessing dose modification factors. For the data cited this predicts compatibility with the hypothesis of a true oxygen "dose-modification" whereas the conventional Pike-Alper analysis does not.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667526     DOI: 10.1259/0007-1285-51-607-534

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  4 in total

1.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Response to X-radiation and cytotoxic drugs of clonal subpopulations of different ploidy and metastatic potential isolated from RIF-1 mouse sarcoma.

Authors:  J G Reeve; K A Wright; P R Twentyman
Journal:  Br J Cancer       Date:  1983-06       Impact factor: 7.640

3.  Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity.

Authors:  J Mircheva; P J Smith; N M Bleehen
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

4.  A comparison of the response to hyperthermia of murine haemopoietic stem cells (CFU-S) and L1210 leukaemia cells: enhanced killing of leukaemic cells in presence of normal marrow cells.

Authors:  R P Symonds; T E Wheldon; B Clarke; G Bailey
Journal:  Br J Cancer       Date:  1981-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.